Antihypertensive Agents

Phase 3Small molecule

NNational Heart, Lung, and Blood Institute (NHLBI)

Antihypertensive Agents is one of 116 small molecule programs targeting Essential Hypertension. It is currently in Phase 3.

Indications

Total Trials

Active Trials

115

Competitors

Pipeline

Status by Indication[3][1]

Indication

Essential HypertensionActive, not recruiting

Cognitive DisorderActive, not recruiting

HypoxemiaActive, not recruiting

HypertensionActive, not recruiting

COVID-19Active, not recruiting

Heart DiseaseActive, not recruiting

Essential HypertensionPreclinical

Active, not recruiting

Cognitive DisorderPreclinical

Active, not recruiting

HypoxemiaPreclinical

Active, not recruiting

HypertensionPhase 3

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

Heart DiseasePhase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Phase 3

1 2

Tricor

JJagotec

Preclinical

1 3

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 4

Statin

Bristol-Myers Squibb

Preclinical

1 5

Tpa

UUniversity of Florida

Preclinical

1 6

Pfizer-Biontech COVID-19 MRNA Vaccine

Pfizer

Preclinical

1 7

BBV152

BBharat Biotech International Limited

Preclinical

4 8

SARS-Cov-2 Bivalent MRNA Vaccine

AAIM Vaccine Co., Ltd.

Preclinical

2 9

AZD 1222

UUniversity Medicine Greifswald

Preclinical

2 10

Serological Test

CCentre Hospitalier de Cornouaille

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Hypertension5 trials

Hypertension Detection and Follow-up Program (HDFP)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000485

Prescribing Patterns of Antihypertensive Drugs in Uncomplicated Hypertension

Completed·UUniversity Hospital, Caen··NCT06517134·3,325,032 enrolled

Control of Hypertension by Non-Pharmacologic Means

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 3·NCT00000498

Show 2 more trials

Postpartum Hypertension, Tight vs Liberal Control Trial

Completed·UUniversity Hospitals Cleveland Medical Center·N/A·NCT04592783·256 enrolled

Multi-provincial Cohort for Hypertension (MUCH)

Unknown status·—··NCT03150888·30,000 enrolled

Essential Hypertension1 trial

To Evaluate Safety and Efficacy of a Radiofrequency Renal Denervation System in Treatment of Essential Hypertension

Completed·SShanghai Golden Leaf MedTec Co. Ltd·N/A·NCT03261375·205 enrolled

Heart Disease1 trial

Multiple Risk Factor Intervention Trial for the Prevention of Coronary Heart Disease (MRFIT)

Completed·UUniversity of Minnesota·Phase 3·NCT00000487

Blood Pressure1 trial

The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly

Completed·RRadboud University Medical Center··NCT05529147·15 enrolled

Hypoxemia1 trial

Clinical Relevance of Nicardipine Induced Hypoxemia in the Intensive Care Unit

Unknown status·UUniversity Hospital, Caen··NCT05155202·300 enrolled

4 more indications

Dialysis Patients1 trial

Blood Pressure in Dialysis Patients

Completed·UUniversity of New Mexico·N/A·NCT01421771·126 enrolled

Intraocular Pressure1 trial

Effects of Systemic Drugs on Intraocular Pressure

Unknown status·—··NCT05328921·200 enrolled

COVID-191 trial

Cardiovascular Risk Factors and Severe COVID-19. A Nationwide Registry-based Case-Control Study

Unknown status·KKarolinska Institutet··NCT04426084·22,784 enrolled

Cognitive Disorder1 trial

The Impact of Dementia and Neurocognitive Disorders on Hypertension Treatment in the Elderly

Completed·—··NCT05845736·353 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Antihypertensive Agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antihypertensive Agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antihypertensive Agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Heart, Lung, and Blood Institute (NHLBI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNational Heart, Lung, and Blood Institute (NHLBI)

Antihypertensive Agents

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Hypertension5 trials

Essential Hypertension1 trial

Heart Disease1 trial

Blood Pressure1 trial

Hypoxemia1 trial

Dialysis Patients1 trial

Intraocular Pressure1 trial

COVID-191 trial

Cognitive Disorder1 trial

References

Drug Info

Quick Facts

Related News